Lexigo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexigo

Quick Facts: Lexigo Identity

Property Description
Active ingredient Betahistine (as dihydrochloride)
Form Oral tablet
Pharmacological class Anti-vertigo agent, Histamine analogue
Common use General management of balance disorders
Origin Synthetic compound

What is Lexigo and its Pharmacological Class?

Lexigo is a synthetic prescription medicine classified under the Anatomical Therapeutic Chemical (ATC) system as an anti-vertigo agent (N07CA01). Its active component is the substance Betahistine, a chemical analogue of histamine, a substance naturally present in the body. This classification applies to the management of vertigo related to vestibular disturbances. The medicine is a single active ingredient product, which is a differentiating factor in its pharmacological profile, ensuring a focused intervention. Lexigo is exclusively available as a prescription medicine (Rx), confirming its use under professional guidance for serious or persistent balance conditions.

Active Ingredient, Presentation, and Purpose

Betahistine's general therapeutic purpose is to provide a stabilizing influence for individuals experiencing symptoms of vestibular dysfunction. A physiological action attributed to the substance is the enhancement of microcirculation within the inner ear. This indicates that the medicine is employed to promote blood flow within the structures responsible for accurate balance signaling. A typical, neutral use scenario involves the sustained management of chronic imbalance, where the goal is to support the stability of the inner ear over time.

Lexigo is supplied as an oral preparation in tablet form. This format ensures its suitability for systemic action and use in management regimens where consistent delivery of the anti-vertigo agent is required to support long-term inner ear function, confirming its role as a foundationally applied medication.

Regulatory References

  1. European Medicines Agency (EMA)
  2. Public Assessment Report (Betahistine)

What side effects are possible with Lexigo?

Possible Side Effects and Safety Information

The safety profile for Lexigo, which contains the active substance Betahistine, is derived from regulatory classifications that organize documented adverse reactions by frequency and physiological system. This information is intended to describe the official risk profile without providing clinical advice.

Frequency-Classified Adverse Reactions

Adverse reactions are classified into categories based on reporting frequency in clinical trials or post-marketing surveillance:

Classification Affected System(s) Examples of Reactions
Common (1 in 100 to 1 in 10 patients) Gastrointestinal disorders, Nervous system disorders Nausea, Dyspepsia (indigestion), Headache
Not Known (Frequency cannot be estimated) Immune System, Skin and Subcutaneous Tissue Hypersensitivity reactions (including Anaphylaxis), Urticaria, Rash, Angioneurotic oedema, Vomiting, Drowsiness

Serious Adverse Reactions and Safety Constraints

Officially documented serious adverse reactions include hypersensitivity reactions, such as Anaphylaxis and Angioneurotic oedema. These reactions are considered clinically significant and are listed with a 'Not Known' frequency.

The medicine is formally contraindicated and should not be used in individuals with a known history of Phaeochromocytoma (a tumor of the adrenal gland) or documented hypersensitivity to Betahistine. Caution is also advised in patients with conditions such as Bronchial Asthma and a history of Peptic Ulcer.

Population-Specific Safety Notes

The official label states that use of Lexigo is not recommended for the paediatric population (under 18 years) due to insufficient data regarding safety and efficacy in this age group. For pregnancy and lactation, safety has not been established; use is generally advised against unless essential. While post-marketing data does not suggest routine adjustments for elderly patients or those with hepatic/renal impairment, general caution is noted.

Overdose and Emergency Response

Lexigo Overdose and When to Seek Help

The official regulatory documentation for Lexigo (Betahistine) specifies the required actions and documented clinical manifestations associated with overdose. Immediate medical attention must be sought if an overdose is suspected.

Documented Clinical Presentations

Reported symptoms following an overdose include common gastrointestinal and CNS effects. These manifestations range from nausea, vomiting, dyspepsia, and abdominal pain to somnolence (drowsiness), ataxia (incoordination), and dryness of the mouth.

Severe Outcomes and Risk Context

More serious complications are documented, including convulsions (seizures), pulmonary complications, and cardiac complications. The official label notes that these life-threatening events were observed especially in cases of intentional overdose or when Lexigo was taken in combination with other overdosed drugs.

Emergency Action and Management

If an overdose occurs, individuals are mandated to contact a doctor, hospital emergency department, or Poison Control Centre immediately. Management of overdose, according to regulatory standards, involves general supportive measures and symptomatic treatment. There is no specific antidote known for Betahistine overdose; procedural steps such as gastric lavage may be utilized within one hour of ingestion.

Therapeutic Uses of Lexigo

What Lexigo Treats: Main Uses and Benefits

Lexigo, which contains the active substance Betahistine, is a therapeutic agent generally used in clinical settings to provide symptomatic support for patients experiencing disorders of the inner ear's balance and auditory systems. It is applied in conditions where symptoms may interfere with daily functioning.

The medicine is primarily prescribed for individuals managing Ménière's disease and similar vestibular conditions. These conditions are characterized by recurrent, challenging symptoms, including pronounced vertigo (spinning sensation), persistent tinnitus, and the feeling of aural fullness.

“The goal is to support the patient during difficult episodes and contribute to easing the overall symptom burden.”

Lexigo is applied in addressing the recurrent, disruptive spinning sensation central to vestibular disorders. By helping manage the impact of these recurring attacks, the medication assists with maintaining a sense of stability and supports general well-being during symptomatic phases.


Quick Fact: Relief for Balance and Auditory Symptoms
Lexigo plays a role in managing symptom clusters that often occur together, offering supportive relief when symptoms intensify and interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lexigo?

The population eligibility for Lexigo (Betahistine) is strictly defined by regulatory documents, distinguishing between absolute prohibitions and populations requiring caution or for whom use is not recommended.


Absolute Contraindications

Lexigo is contraindicated and must not be used by the following groups:

  • Patients with Phaeochromocytoma (a tumor of the adrenal gland).
  • Individuals with a known hypersensitivity to the active substance, Betahistine, or any of the inactive ingredients.

Population and Condition Restrictions

Population Status Regulatory Rule
Pediatric Use Not recommended for children and adolescents under 18 years due to insufficient data on safety and efficacy.
Pregnancy/Lactation Should be avoided during pregnancy and is not recommended while breastfeeding.
Comorbidities Caution is advised for patients with bronchial asthma or a history of peptic ulceration; these patients should be carefully monitored.
Organ Function Adults with hepatic (liver) or renal (kidney) impairment are generally eligible, as post-marketing experience suggests no specific dose adjustment is necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns for Lexigo (Betahistine) as verified by government regulatory authorities.

Pharmacokinetic and Metabolic Interactions

Co-administration of Lexigo with Monoamine Oxidase Inhibitors (MAOIs), including selective MAO-B inhibitors such as selegiline, is documented in regulatory labeling as potentially causing an inhibition of Betahistine metabolism. This official finding indicates an increased exposure of Lexigo and therefore requires caution during concomitant use. In contrast, based on in vitro data, the official regulatory finding is that no in vivo inhibition on Cytochrome P450 enzymes is expected when Lexigo is administered.

Pharmacodynamic and Food Interactions

Interacting Substance Official Regulatory Outcome/Classification
Histamine H1 Antagonists (Antihistamines) Theoretical mutual attenuation of effect is expected due to the substance's opposing actions
Food Intake Slowing of absorption (lower C max) is observed, but total absorption (AUC) is similar

No specific drug-drug combinations are officially listed as absolute contraindications in the drug interaction sections of the regulatory documents. The interaction structure is defined by MAOI-related exposure risks, a theoretical pharmacodynamic effect with antihistamines, and the constraint that food slows the absorption rate without altering the total amount of the substance absorbed.

Mechanism of Action

Central Facilitation of Vestibular Adaptation

Lexigo exerts its action through a dual modulation of the histaminergic system. The primary mechanism involves functioning as an H3 receptor antagonist (or inverse agonist) in the central nervous system (CNS). This H3 R blockade disinhibits the histaminergic system, leading to an increase in the synthesis and release of endogenous histamine into the vestibular nuclei. This molecular cascade modulates neuronal excitability, which accelerates the process of central vestibular compensation and facilitates long-term central vestibular processing.


Targeted Peripheral Microcirculatory Modulation

Concurrently, the drug exhibits a weak partial agonism at H1 receptors located on the microvasculature within the inner ear. This interaction induces localized vasodilation, leading to increased vestibulocochlear blood flow. This physiological change aids the regulation of fluid dynamics and enhances local perfusion.


Mechanism Constraint: Time-Dependent Physiological Outcome

The mechanism relies on neuronal plasticity, a time-dependent biological process. Consequently, the full manifestation of its physiological effects—the influence on vestibular processing—is constrained to emerge gradually over a continuous period of weeks or months.

Dosage and Administration Information

How to Use Lexigo: Official Administration Guidelines

Lexigo (betahistine dihydrochloride) is an oral medication that must be used strictly according to the administration guidelines detailed in official prescribing information. The instructions below describe the standardized approach for its usage, which is based on standardized prescribing standards.


Administration Scope

Parameter Official Instruction (Strictly Label-Based)
Route of administration Oral use only.
Dosing schedule (Adults) The total daily dose typically ranges from 24 mg to 48 mg. The dose is individually adapted based on clinical response, and the maximum recommended daily dose is 48 mg.
Frequency pattern The total daily dose is administered in two or three divided doses (BID or TID) spread throughout the day.
Timing in relation to meals The tablets should be taken preferably with or after meals.

Administration Requirements and Use Over Time

Lexigo tablets must be swallowed whole with water and must not be chewed. Administration with or after food is specified to help mitigate the possibility of mild stomach complaints. Some strengths (e.g., the 16 mg tablet) may feature a score line to facilitate breaking into equal doses for flexible adjustment, whereas a score line on other formulations may be intended only to aid in swallowing.

Treatment with Lexigo is generally long-term, extending over several months to manage the condition. Optimal response may take a few months to achieve. Use in children and adolescents under 18 years of age is not recommended due to insufficient data. Dose adjustment is not necessary for older adults or in cases of renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lexigo

This overview summarizes the official clinical research and scientific studies that have examined Lexigo's active ingredient, Betahistine, according to authoritative governmental and intergovernmental sources. The information focuses only on the types of research conducted, the outcomes measured, and the limitations noted in the evidence landscape.


Evidence for Use in Managing Ménière's Disease

Lexigo was studied by researchers examining symptoms of Ménière's disease, a condition characterized by fluctuating or episodic manifestations such as recurrent vertigo and associated auditory symptoms. The research base includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Researchers monitored outcomes related to episodic or acute changes in symptoms, specifically the frequency and intensity of vertigo attacks, often relying on patient diaries. Systematic reviews often conclude that the certainty remains low for a definitive, consistent group pattern concerning vertigo frequency, as findings were mixed across major high-quality studies.


Evidence for Use in Peripheral Vestibular Vertigo

Research explored settings involving a broader range of conditions where symptoms may vary in intensity of vertigo originating from the peripheral vestibular system. Studies included both older placebo-controlled clinical trials and large-scale observational settings where daily-life functioning was evaluated. The outcomes research examined centered on patient-reported outcomes describing severity of vertigo and dizziness. The evidence quality varies across studies, and the data gathered primarily provides insight into short-term changes in patient reports.


What is Still Uncertain About Lexigo's Evidence Base

Research has explored the course of treatment over defined time intervals, but the evidence for truly long-term effects are not fully established by definitive controlled trials. Data for certain groups remain insufficient regarding the use in populations outside of general adult study participants, such as children or pregnant individuals. A major limitation is the inconsistency in findings across several major trials for Ménière's disease. Additionally, many measured outcomes are highly subjective (relying on patient self-reports), and comparative evidence is lacking in some contexts.

Key Studies & References Public Assessment Report: Scientific discussion Betahistine Amarox 8 mg, 16 mg and 24 mg tablets (National Competent Authority Regulatory Assessment)

Frequently Asked Questions (FAQ)

Common questions about Lexigo (FAQ)

Q: How long does Lexigo typically take before people notice an effect?

According to official regulatory documents, Lexigo's effect is time-dependent, meaning improvement emerges gradually. Some users may start to notice an initial change after about two weeks, although the maximum benefit or optimal clinical result is typically achieved only after several months of continuous treatment.

Q: How long can someone generally stay on Lexigo?

Treatment with Lexigo is generally described as a long-term approach, extending over several months to manage the condition. Official documentation states that the precise length of time someone should take the tablets is determined by their healthcare provider and can vary among individuals based on their clinical needs.

Q: Is it normal to feel tired or dizzy when starting Lexigo?

Regulatory safety documents indicate that dizziness is listed as a common side effect for the active substance in Lexigo. However, drowsiness is generally listed with a frequency that cannot be estimated from the available regulatory data. If dizziness or drowsiness is persistent or severe, consulting a health professional for guidance is important.

Q: Can Lexigo be taken on an empty stomach?

Official guidelines recommend taking the tablets preferably with or after meals. Taking Lexigo with food helps to mitigate the possibility of experiencing mild stomach complaints. Pharmacokinetic studies show that while food slows the rate of absorption, the total amount of the medicine absorbed by the body remains similar.

Q: What are common user misconceptions about Lexigo that official sources clarify?

Official documents clarify that the medicine's mechanism involves neuronal plasticity, a time-dependent biological process. This means the full physiological effects do not happen instantly but emerge gradually over a period of weeks or months, addressing the common expectation of a rapid, immediate change.

Q: Are there generic versions of Lexigo available?

Yes, the active ingredient in Lexigo, Betahistine, is a well-established substance. It is available under various generic and brand names in different regions and is documented in multiple national drug registries.

Q: Does Lexigo cause weight gain or weight loss?

Official regulatory safety information does not list either weight gain or weight loss in the categorized adverse reaction profile for this medicine (Common, Uncommon, etc.).

Q: Can Lexigo affect my sleep patterns?

Sleep disturbance is not specifically listed as a common side effect. However, official safety documents do include drowsiness as a possible adverse reaction, classifying its frequency as Not Known, meaning it cannot be reliably estimated from available data.

Q: Is Lexigo chemically similar to other drugs used for the same purpose?

Lexigo's active ingredient, Betahistine, is officially classified as a histamine analogue (a substance chemically related to the naturally occurring substance histamine in the body) and an anti-vertigo agent. This classification defines its focused intervention for balance disorders.

Q: Can Lexigo cause changes in mood or behavior?

Changes in mood or behavior are not explicitly listed as specific side effects in official regulatory documents. However, the safety profile does include general undesirable effects related to the Nervous system disorders.

Q: What is the half-life of Lexigo (how long does it stay in the system)?

Pharmacokinetic data from regulatory sources show that the active substance is rapidly metabolized in the body. The main breakdown product has an elimination half-life of approximately 3.5 text hours, and it is virtually all excreted from the body within 24 hours.

Q: Is there any public research on Lexigo's effectiveness in children?

Official guidelines state that use in children and adolescents under 18 years of age is not recommended. This is because regulatory authorities have determined there is insufficient data regarding the medicine's safety and efficacy in this pediatric age group.

Q: Are allergic reactions to Lexigo common?

Serious allergic reactions, including anaphylaxis and hypersensitivity, are officially listed as a possible adverse reaction. However, their frequency is classified as Not Known, indicating the available regulatory data is insufficient for an estimate.

Q: Does Lexigo affect blood pressure?

Official safety documents list a contraindication for individuals with Phaeochromocytoma, a tumor that can cause high blood pressure. Caution and monitoring are also advised for patients who have low blood pressure (hypotension).

Q: Has Lexigo been approved in countries outside of the US?

Yes, Lexigo's active ingredient, Betahistine, is approved and regulated by major governmental and intergovernmental agencies globally. It is commonly used in countries covered by bodies like the European Medicines Agency (EMA) and the UK MHRA.

Q: How is Lexigo eliminated from the body?

According to official pharmacokinetic data, after the drug is rapidly broken down by the body, the primary breakdown product is eliminated almost completely via renal excretion, meaning it is passed out through the urine.

Q: Why is it important to follow the specified instructions for using Lexigo?

Official guidelines recommend specific steps, such as taking the tablets with or after meals to help reduce the possibility of mild stomach complaints. Furthermore, long-term, consistent use is emphasized to allow for the time-dependent emergence of the full physiological effect on the balance system.

How should Lexigo be stored and disposed of?

How to Store and Dispose of Lexigo

Storage Requirements

Lexigo (Betahistine) tablets must be stored at a temperature not exceeding 30°C (86°F). The product must be protected from light and moisture to maintain its stability, requiring it to be kept in the original blister pack or container until the time of use.

Child-Safety and Stability

It is a mandatory safety requirement to keep this medicine out of the sight and reach of children.

Product stability is tied to the labeled expiry date, provided the required storage conditions are strictly followed.

Disposal Instructions

Unused or expired Lexigo must be disposed of properly. Regulatory instructions mandate that the medicine must not be thrown away via wastewater or routine household waste. Patients should consult their pharmacist on the proper method to discard unneeded medicine in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexigo found in:

A-Z Index: